<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116727</url>
  </required_header>
  <id_info>
    <org_study_id>20021635</org_study_id>
    <secondary_id>016.0035</secondary_id>
    <nct_id>NCT00116727</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis DMARD Intervention and UtilizationStudy</brief_title>
  <official_title>Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      To systematically collect and document use patterns, effectiveness and safety of DMARD
      treatments currently used in the management of rheumatoid arthritis. The primary purpose of
      this study is to estimate the incidence of serious adverse experiences and adverse
      experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5103</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <description>etanercept 50 mg/wk SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENBREL®</intervention_name>
    <description>50 mg/wk SC</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RA patients (by ACR criteria) starting on etanercept alone or in combination with other
        DMARDs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfillment of the 1987 American Rheumatism Association criteria for RA

          -  Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition
             to their current DMARD therapy)

        Exclusion Criteria:

          -  Currently or previously enrolled in RADIUS 1

          -  Currently enrolled in a clinical trial where treatments or patient visits are imposed
             by a protocol

          -  Active infections

          -  Known allergy to ENBREL® or any of its components

          -  Current treatment with ENBREL®

          -  Patients who have previously been demonstrated to be intolerant of or refractory to
             ENBREL® therapy

          -  Nursing or pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2005</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>DMARD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

